Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Pancreatic Cancer Condition: Locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas |
Dose: Intravenous infusion – 1000 mg/m² Frequency: once weekly Duration: 7 weeks; rest 1 week, then 1000 mg/m² intravenous on Days 1, 8, and 15 of each 28-day cycle Note: Administer over 30 minutes. Various regimens exist including monotherapy and in combination with other chemotherapy agents (e.g., erlotinib, paclitaxel protein bound, capecitabine) |
|
Indication: Non-small Cell Lung Cancer |
Dose: Intravenous infusion – 1000 mg/m² Frequency: on days 1, 8, and 15 of each 28-day cycle Note: Administer over 30 minutes. Administer cisplatin 100 mg/m² intravenous after gemcitabine on day 1 |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- For IV use only
- Must be diluted properly
Side Effect
- N/V (69%)
- Anemia (65%)
- Elev LFTs (68%)
- Neutropenia (63%)
- Leukopenia (62%)
- Pain (48%)
- Proteinuria (45%)
- Fever (41%)
- Hematuria (35%)
- Rash (30%)
- Thrombocytopenia (24%)
- Dyspnea (23%)
- Constipation (23%)
- Diarrhea (19%)
- Flu-like syndrome (19%)
- Hemorrhage (17%)
- BUN increased (16%)
- Infection (16%)
- Alopecia (15%)
- Edema (13%)
- Elev bilirubin (13%)
- Paresthesia (2-10%)
- Creatinine increased (2-8%)
- Injection site reactions (4%)
- Bronchospasm (2%)
- Oesophagitis and pneumonitis when given with radical radiotherapy to the thorax
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Warfarin
|
May increase the anticoagulant effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Concurrent radical radiotherapy
|
Increased toxicity risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 25° C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.